Analysts Set Catalyst Biosciences Inc (CBIO) Target Price at $23.88

Catalyst Biosciences Inc (NASDAQ:CBIO) has been assigned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $23.88.

CBIO has been the topic of several research reports. Oppenheimer initiated coverage on Catalyst Biosciences in a research note on Friday, January 4th. They set an “outperform” rating and a $24.00 price objective on the stock. CIBC initiated coverage on Catalyst Biosciences in a research note on Friday, January 4th. They set an “outperform” rating and a $24.00 price objective on the stock. Finally, Zacks Investment Research cut Catalyst Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

CBIO traded down $0.02 on Friday, reaching $8.70. The company’s stock had a trading volume of 131,907 shares, compared to its average volume of 171,269. The company has a market capitalization of $103.95 million, a P/E ratio of -3.25 and a beta of 2.45. Catalyst Biosciences has a 1 year low of $6.20 and a 1 year high of $29.95.

Catalyst Biosciences (NASDAQ:CBIO) last issued its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.16). Sell-side analysts anticipate that Catalyst Biosciences will post -3.79 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CBIO. Rhumbline Advisers raised its stake in Catalyst Biosciences by 43.1% during the fourth quarter. Rhumbline Advisers now owns 17,000 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 5,120 shares in the last quarter. D. E. Shaw & Co. Inc. raised its stake in Catalyst Biosciences by 60.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 25,100 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 9,500 shares in the last quarter. Requisite Energy Fund I LP acquired a new stake in shares of Catalyst Biosciences during the 4th quarter worth approximately $256,000. National Asset Management Inc. raised its position in shares of Catalyst Biosciences by 40.0% during the 4th quarter. National Asset Management Inc. now owns 35,000 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 10,000 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Catalyst Biosciences by 1,127.7% during the 4th quarter. Bank of America Corp DE now owns 58,559 shares of the biopharmaceutical company’s stock worth $462,000 after purchasing an additional 53,789 shares during the period. Hedge funds and other institutional investors own 62.70% of the company’s stock.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Story: Trade Deficit

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.